BioHarvest Sciences Inc

BioHarvest Sciences Inc operates with a liquidity position that is relatively strong for a pre-revenue biotech, with $23.0 million in cash and equivalents and a current ratio of 3.97, indicating the company can cover short-term obligations multiple times over. However, the company reported negative operating cash flow of $7.2 million and free cash flow of $11.9 million, reflecting ongoing operational losses and capital expenditures. Profitability metrics show significant underperformance relative to industry norms. The company reported a return on equity of -43.76% and a return on assets of -23.36%, both well below the median for the Pharmaceuticals industry. Gross profit of $20.5 million was insufficient to offset operating expenses, resulting in a net loss of $11.1 million. These metrics suggest the company is not yet generating sustainable returns on invested capital. The company's revenue is split between two segments: Nutraceuticals and Pharmaceuticals. While VINIA is the primary commercial product in the Nutraceuticals segment, the company's overall revenue concentration remains undisclosed in the latest filings. No geographic breakdown is provided, but the company's operations are likely concentrated in North America, given the location of its headquarters and the nature of its market. Growth trajectory is constrained by current financial performance. The company reported total revenue of $34.5 million in the latest period, but no year-over-year growth data is available. The outlook for the current fiscal year does not include revenue growth, and no specific guidance is provided for the next fiscal year. The company's reliance on contract development and production services and nutraceutical sales suggests a need for significant R&D investment to scale operations. Risk factors include the company's negative net income and operating cash flow, which could pressure liquidity if cash burn accelerates. The debt-to-equity ratio of 0.55 is moderate, but the company has $14.1 million in long-term debt. No immediate dilution risks are flagged, and shares outstanding remain unchanged between basic and diluted shares. However, the company's negative free cash flow and ongoing losses could necessitate future capital raises, which may involve dilution. Recent events include the continued commercialization of VINIA and ongoing R&D efforts in botanical synthesis. No material regulatory or litigation events were disclosed in the latest filings. The company's 10-K filing outlines ongoing development of new therapeutic solutions and expansion of its contract development services.